Truist Financial analyst David S Macdonald reiterated a Buy rating on AdaptHealth (AHCO – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $10.00.
According to TipRanks, S Macdonald is a 5-star analyst with an average return of 12.5% and a 67.41% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as DaVita, Humana, and Quest Diagnostics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AdaptHealth with a $10.00 average price target, which is a 0.00% upside from current levels. In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
Based on AdaptHealth’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $804.03 million and a GAAP net loss of $454.08 million. In comparison, last year the company had a GAAP net loss of $2.59 million
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AHCO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AdaptHealth (AHCO) Company Description:
AdaptHealth Corp. provides medical products for both rental and sale. It focuses on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers, and hospital beds. The company was founded in 2012 and is headquartered in Plymouth Meeting, PA.
Read More on AHCO:
